Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study-Reference-Cited by-同舟云学术

Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study

Published:2018-03-31 Issue:7 Volume:37 Page:2226-2233
ISSN:0733-2467
Container-title:Neurourology and Urodynamics
language:en
Short-container-title:Neurourology and Urodynamics

Author:

Krhut Jan¹^ORCID,Borovička Vladimír²,Bílková Karolína³,Sýkora Radek¹,Míka David¹,Mokriš Jan²,Zachoval Roman²^ORCID

Affiliation:

1. Department of Urology; University Hospital; Ostrava Czech Republic

2. Department of Urology; Thomayer Hospital; Prague Czech Republic

3. Spinal Cord Rehabilitation Unit; Rehabilitation Center; Kladruby Czech Republic

Funder

Astellas Pharma

Publisher

Wiley

Subject

Urology,Clinical Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/nau.23566/fullpdf

Reference26 articles.

1. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction;Haylen;NeurourolUrodyn,2010

2. The management of neurogenic lower urinary tract dysfunction after spinal cord injury;Wyndaele;Nat Rev Urol,2016

3. GENULF: The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines;de Sèze;MultScler,2007

4. Effect of imidafenacin on the urodynamic parameters of patients with indwelling bladder catheters due to spinal cord injury;Sugiyama;Spinal Cord,2017

5. Constipation and LUTS-How do they affect each other;Averbeck;IntBraz J Urol,2011

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

2. Efficacy and Safety of Mirabegron Add-on Therapy After Failure With Solifenacin in Multiple Sclerosis Patients With Overactive Bladder: A Pilot Study;Clinical Neuropharmacology;2024-05-14

3. Bladder Compliance;Urologic Clinics of North America;2024-05

4. Consensus update on the therapeutic approach to patients with neurogenic detrusor overactivity;Actas Urológicas Españolas (English Edition);2024-05

5. Actualización del consenso sobre el abordaje terapéutico del paciente con hiperactividad neurógena del detrusor;Actas Urológicas Españolas;2024-05